2018 in review: gynecologic cancer insights

Abstract

Gynecologic cancers constitute an important burden of disease around the world. Estimates from GLOBOCAN 2018 reveals approximately 1,247,300 incident casesand 596,000 related deaths of cancers of the uterine cervix, corpus uteri, and ovarian, annually around the world. In 2018 lots of promising results to improve disease control have been presented at international gynecological cancer meetings. The current review highlights some of the top gynecologic cancer news of 2018, including the new standard of care for BRCAmutant ovarian cancer patients with maintenance olaparib in first line, benefit of bevacizumab rechallenge for relapsed ovarian cancer patients, and the unexpected results of worse overall survival with minimally invasive surgery in early cervical cancer, among others.